Results 41 to 50 of about 8,134 (194)

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan

Therapeutic Advances in Cardiovascular Disease, 2019
Background: Although tolvaptan, an electrolyte-free water diuretic for congestive heart failure (HF), is reported to have no effect on long-term mortality or HF-related morbidity, there may exist some subgroups of patients who may receive beneficial ...
Kensuke Fujioka, Sumio Mizuno, Taro Ichise, Takao Matsui, Hiroaki Hirase, Masato Yamaguchi, Takahiko Aoyama, Masakazu Yamagishi, Noboru Fujino, Masa-aki Kawashiri, Kenshi Hayashi   +10 more
doaj   +1 more source

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia

BMC Gastroenterology, 2018
Background Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients.
Shuzhen Wang, Xin Zhang, Tao Han, Wen Xie, Yonggang Li, Hong Ma, Roman Liebe, Honglei Weng, Hui-Guo Ding   +8 more
doaj   +1 more source

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

BMC Nephrology, 2022
Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4).
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger   +7 more
doaj   +1 more source

Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5

Kidney International Reports
Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Akinari Sekine, Junichi Hoshino, Toshio Mochizuki, Shinya Nakatani, Saori Nishio, Tatsuya Suwabe, Hiroki Hayashi, Hirayasu Kai, Koichi Seta, Fumihiko Hattanda, Sumi Hidaka, Kazushige Hanaoka, Mahiro Kurashige, Hiroshi Kataoka, Kiyotaka Uchiyama, Keiji Shimazu, Eiji Ishikawa, Yosuke Shimada, Haruna Kawano, Ken Tsuchiya, Shigeo Horie, Ichiei Narita, Yoshitaka Isaka, Satoru Muto   +23 more
doaj   +1 more source

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

BMC Nephrology, 2019
Background The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to ...
Hayley Bennett, Phil McEwan, Karina Hamilton, Karl O’Reilly   +3 more
doaj   +1 more source

Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study

Annals of Hepatology, 2017
Introduction and aim: Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excretion, but its efficacy and safety in cirrhotic
Ji-Dong Jia, Wen Xie, Hui-Guo Ding, Hua Mao, Hui Guo, Yonggang Li, Xiaojin Wang, Jie-Fei Wang, Wei Lu, Cheng-Zhong Li, Yimin Mao, Gui-Qiang Wang, Yue-qiu Gao, Bangmao Wang, Qin Zhang, Yan Ge, Vincent Wai-Sun Wong   +16 more
doaj   +1 more source

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial) [PDF]

, 2013
Serum magnesium levels may be impacted by neurohormonal activation, renal function, and diuretics. The clinical profile and prognostic significance of serum magnesium level concentration in patients hospitalized for heart failure (HF) with reduced ...
Ambrosy, Andrew P, Butler, Javed, Fonarow, Gregg C, Gheorghiade, Mihai, Greene, Stephen J, Investigators, EVEREST Trial, Konstam, Marvin A, Maggioni, Aldo P, Mentz, Robert J, Nodari, Savina, Subacius, Haris P, Vaduganathan, Muthiah, Zannad, Faiez   +12 more
core   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

Angewandte Chemie International Edition, EarlyView.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +1 more source

Hyponatremia : Special Considerations in Older Patients [PDF]

, 2014
Acknowledgments Roy L.
Clarke, Jennifer M, Cumming, Kirsten, Myint, Phyo K, Soiza, Roy L, Wood, Karen M   +4 more
core   +2 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source